When you think of the Barefoot Contessa, you may think of complicated recipes using expensive and obscure ingredients like truffle butter or fleur de sel salt. However, the baking ingredient Ina Garten always keeps in her pantry is neither expensive nor obscure. According to Food & Wine, Garten's secret to enhancing the flavor of her baked goods, including her Outrageous Brownies, is the addition of instant coffee.
Some of Garten's recipes call for instant coffee while others use espresso powder, and she clarifies the difference between the two on her website, explaining that she decides which one to use based on how much coffee flavor she wants to add to a recipe. Her Black & White Cookies recipe calls for half a teaspoon of instant coffee, but she uses a full tablespoon of Medaglia d'Oro, her preferred espresso powder, when she makes her decadent Peanut Butter Globs (per Food Network).
The FDA recently published “Sameness Evaluations in an ANDA – Active Ingredients,” a new draft guidance detailing recommendations for demonstrating sameness between the active ingredient in a proposed generic drug product and its reference listed drug (RLD), as required under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and related regulations.
Background on sameness within the generic drug approval pathway
Under the 1984 Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Amendments), a generic drug application may rely on evidence showing that its referenced brand name drug (reference listed drug or RLD) is safe and effective to support market approval.
In order to qualify for such reliance, the generic drug sponsor must show that its product is the “same” as the RLD. By definition, “same as” means “identical in active ingredient(s), dosage form, strength, route of administration, and conditions of use, except that conditions of use for which approval cannot be granted because of exclusivity or an existing patent may be omitted.”[1] Additionally, the abbreviated new drug application (ANDA) sponsor must show that its product is bioequivalent to the RLD, meaning there is no significant difference between the RLD’s and generic drug’s rates and extent of absorption when administered at the same dose of the therapeutic ingredient under similar experimental conditions.
General considerations for determining the active ingredient
First, the Agency’s draft guidance offers general considerations to help ANDA applicants understand what FDA considers an active ingredient and discusses the need to “fully evaluate the potential for changes in or to the active ingredient during the manufacturing process.”
As noted in the guidance, the FDA maintains “broad discretion” to determine the sufficiency of information submitted to support a sameness argument in an ANDA. One possible approach to this determination is to consider whether the active ingredient in question meets the applicable pharmacopeial (USP) standard of identity. If no USP standard of identity exists, then the Agency recommends establishing identity, and, by extension, ingredient sameness, through appropriate analytical methods such as high-performance liquid chromatography or titration. In some cases, the FDA may prescribe additional standards to help determine sameness.
A drug product’s active ingredient is defined as “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of man or other animals” (21 CFR 210.3(b)(7)). The active ingredient, which “may undergo chemical change in the manufacture of the drug product and be present in the drug product in a modified form intended to furnish the specified activity or effect,” is evaluated for sameness as it exists in the drug’s finished dosage form – for example, the tablet, capsule or solution which contains the drug substance. The definition covers the entire molecule, including portions that cause the drug to be an ester or salt. For the purposes of determining sameness, “noncovalent derivatives of the molecule,” such as complexes, chelates or clathrates, are also relevant.
According to the guidance, some active ingredients have multiple physical forms that differ in structure (eg, polymorphs or co-crystals). While these may pose unique regulatory challenges, the draft guidance states that differences in physical form will not prevent a prospective ANDA applicant from demonstrating active ingredient sameness between the generic drug product and the RLD.
Active ingredient sameness considerations in certain drug products
The draft guidance also provides several considerations for sameness with respect to synthetic peptide and complex mixture drug products. For instance, an ANDA applicant proposing a generic synthetic peptide drug product could use “physicochemical characterization and biological evaluation” to demonstrate sameness with an RLD. The Agency recommends that applicants perform comparative testing for the proposed generic synthetic peptide to the RLD even if appropriate compendial standards are available for an ANDA.
As another example, the guidance discusses the FDA’s approach to evaluating sameness of proposed complex mixtures. In these cases, the FDA will consider the totality of relevant evidence submitted in an ANDA to determine whether the mixture’s active ingredient(s) have been properly characterized for purposes of assessing sameness, and the Agency further recommends that orthogonal methods be applied to describe components of the mixture – for example, using “multiple batches of both the proposed generic drug product (test product) and reference product under similar conditions.”
The guidance notes that the FDA has identified various categories of complex mixtures, including naturally derived mixtures with multiple components, synthetic polymers and synthetic or semi-synthetic mixtures. The Agency treats most of these complex mixtures as a single active ingredient due to the inability to distinguish each constituent component in the mixture that meets the definition of “active ingredient.”
However, if it is possible to distinguish more than one individual constituent component and its pharmacological effects, the FDA will treat each constituent component as a separate active ingredient. Although ANDAs for fixed-combination drug products also require a showing of sameness for every active ingredient present, the guidance states that they are distinct from complex mixtures as described here because separate active ingredients in a fixed-combination drug are intentionally combined so that each component makes a contribution to the claimed effects (defined at 21 CFR 300.50).
Thus, in order to support an active ingredient sameness determination, the FDA recommends that applicants of ANDAs for complex mixtures characterize components of the mixture using the multiple batch method. Additionally, the guidance suggests that sponsors “propose ranges for each molecule in common based on the comparative testing” and provide a justification for the ranges.
Characterization of the active ingredient in the drug product
Lastly, the draft guidance outlines how sponsors should characterize active ingredients for drug products, as well as provides a non-exhaustive list of active ingredient characterization examples.
The draft guidance notes that the chemical form of the active ingredient is typically the “same as the chemical form introduced at the start of drug product manufacture.” However, for a proposed generic drug product with an active ingredient that undergoes a chemical change during manufacture, the FDA will generally evaluate sameness based on the converted chemical form of the active ingredient, as present in the finished dosage form of the RLD.
The Agency goes on to note that, in the event that the chemical form(s) of the active ingredient do not appear in the drug product formulation in a “consistent or known manner,” the prospective applicant may contact the Office of Generic Drugs during product development, as the draft guidance may not specifically address how to demonstrate sameness under these unique circumstances.
Impact on generic drug ANDAs
Despite providing a great deal of color around the definition and characterization of “active ingredient,” the non-binding draft guidance nonetheless contains open-ended language that describes potential approaches without closing the door to other conceivable sameness evaluation methods the FDA may apply at its discretion. The FDA also encourages sponsors to review product-specific guidances for generic drug development, as these may also “include recommendations on how to demonstrate active ingredient sameness.” In addition, the FDA invites prospective ANDA applicants to request a meeting with the Office of Generic Drugs to discuss proposed methods for establishing sameness before submitting an ANDA, which may ultimately help streamline the application process.
Furthermore, the FDA recognizes in its draft guidance that, as science and technology continue to evolve, sponsors may be required to characterize and quantify the sameness of their potential generic drugs without applicable guidance. To address this issue, the Agency will need to continue revisiting the various ways prospective ANDA applicants may adequately demonstrate sameness.
The comment period is scheduled to close on January 9, 2023. We will continue to monitor any further developments and provide timely updates on this topic. For information about this evolving FDA guidance, please contact your DLA Piper relationship partner, the author of this alert or any member of our FDA practice group.
If you've been known, from time to time, to indulge in a slightly boozy Irish coffee, then chances are you'd also love this silky Irish Cream Chocolate Fondue from Tasting Table recipe developer Jessica Morone. Along with the standard fondue ingredients of heavy cream and chopped chocolate — in this case a semi-sweet variety — Morone mixes in Irish cream, that sweet mixture of Irish whiskey, cream, and sugar (via Baileys).
Cream on cream? You better believe it. "The addition of the Irish cream to the chocolate gives it a delicious, complex flavor," Morone tells Tasting Table. And she doesn't skimp on the deliciousness, either, adding a generous ⅓ cup of the stuff to her fondue. "There is a good amount of Irish cream in this recipe so you can really taste the added flavor," she says. So the next time you're craving a participatory dessert that's evocative of a 1970s Swiss chalet, do a little border-jumping and grab your favorite bottle of Irish cream, too.
Ki’Leaft is a 100% natural COSMOS-certified extract of kiwi (Actinidia chinensis) leaves. The new active ingredient is upcycled [1] from crop by-products from farms located near the Berkem Group’s extraction plant, in Dordogne, in the south-west of France.
Sugars and polyphenols
According to Berkem, Ki’Leaft meets market needs in new naturel active ingredients offering antioxidant, firming and regenerative properties, while also reinforcing the skin’s barrier function.
The culmination of 10 years of research and development Ki’Leaft is an active ingredient rich in sugars and containing polyphenols [2].
Clinical studies have shown that Ki’Leaft provides an immediate tightening effect, contributes to skin regeneration, and strengthens the skin’s barrier function and structure. It also shows a high antioxidant capacity.
“Ki’Leaft meets the cosmetics market’s expectations by offering benefits for the facial care market (serum, face treatments, etc.) which has experienced annual worldwide growth of 10% since 2020, [3]” highlights Berkem.
Upcycling and short supply chains
Located near the main French kiwifruit farms, the Berkem factory in Gardonne, in the south-west of France, benefits from an easily accessible source of raw materials from controlled and certified organic cultivation. Indeed, the Nouvelle Aquitaine region accounts for 75% of French kiwi production.
While the leaf picked with the fruit is mostly discarded during harvest, the new active ingredient developed by the Berkem Group brings this renewable resource to a second and high-value life.
“With 30 years of experience in plant extraction, Groupe Berkem, a developer of plant-based chemistry solutions, constantly seeks to be a pioneer of innovative solutions in the field of health, beauty and nutrition sectors. The development of this new active ingredient with remarkable benefits by upcycling meets the demands of our customers in the cosmetics industry, both professionals and major brands, while also illustrating our Group’s CSR commitments,” says Charlène Martin, Marketing Manager, Groupe Berkem.
New form of Rhodiolife® will expand the range of delivery systems for this adaptogen ingredient
MORRISTOWN, N.J., Nov. 28, 2022 /PRNewswire/ -- PLT Health Solutions, Inc announced that it has begun offering its Rhodiolife®Rhodiola rosea ingredient in a water-soluble form in North America. This has the potential to dramatically expand the types of consumer products into which it can be formulated, tapping the consumer trend for new and more convenient delivery systems. The work on developing this new product form was recently completed by PLT innovation partner Nektium Pharma (Las Palmas, Spain). It included a full suite of applications and shelf-life testing in beverages that confirm that water-soluble Rhodiolife will not impact the color or flavor of formulations and that the active components of the adaptogen remain stable through processing and ultimate consumer use.
According to Devin Stagg, Chief Operating Officer for PLT Health Solutions, the availability of a water-soluble form of Rhodiolife points to the continuing innovation Nektium is putting behind this ingredient. "Beverage formulation is challenging. Nektium Pharma's studies with Rhodiolife and beverage formulations show that it meets industry standards for performance in processing and that color, flavor and the bioactives content are shelf-stable. This means we can now deliver the benefits of Rhodiolife in beverages and other delivery systems," he said. "The real innovation of this new water-soluble Rhodiolife is that it allows a premium Rhodiola rosea – containing the rosavins and salidroside found in the actual plant root - to be formulated into challenging beverage systems easily and consistently. This will allow faster and more cost-effective product development and ultimately a better consumer experience," he added.
Studies demonstrate stability and quality retention
Studies conducted by Nektium Pharma used a low pH orange flavored formulation. Over the study period, it was confirmed that the introduction of Rhodiolife did not affect the Brix or pH of the orange beverage. There was no change in either the flavor or color profile. It was also observed that there was no change in total rosavins content. Previous studies with Rhodiolife have shown that its main bioactives – rosavins and salidroside – are very resistant to thermal degradation both as a powder and in aqueous solutions. In this study, pasteurization did not have any effect on the physical and sensory properties of the orange beverage.
Setting the standard for Rhodiola quality
The availability of a water-soluble form of Rhodiolife broadens the product types that can take advantage of this premium ingredient. To ensure consistent quality, Nektium's Quality Assurance team conducts multiple identity tests on every batch of Rhodiolife, including macroscopic and sensorial analysis, the development of chromatographic profiles and independent DNA barcode analysis to ensure the authenticity of the raw material. A gentle extraction process is used to unlock the active ingredients while preserving the natural phytochemical profile of the root. The material is then standardized to provide precise levels of bioactive compounds. The resulting HPLC 'fingerprint' of the Rhodiolife extract is consistent from batch to batch and matches with that of the native root.
According to Stagg, it is this fingerprint that signals to the consumer that they are getting a quality product. "Only Rhodiolife's unique fingerprint composition consistently provides the spectrum of compounds found in the root of the plant that are responsible for its biological activity – including rosavin, rosarin, rosin and salidroside. With Rhodiolife, not only is the percentage of the primary actives the same as the root, but so is the ratio of actives. This is not the case with many other Rhodiola rosea ingredients on the market," he said.
Deborah Thoma, Marketing Manager of Nektium Pharma discussed the motivation behind and impact of this new Rhodiolife product form. "Successful beverage formulations require very special performance parameters from their ingredients. Our testing has shown we have accomplished this task. We feel that this new form of Rhodiolife can deliver adaptogen benefits into virtually any beverage product – and also into foods that feature the use of aqueous phase production," Thoma said.
This water-soluble version of Rhodiolife is part of a continuing program of innovation surrounding this ingredient. In September of this year, PLT and Nektium announced that they have begun offering Rhodiolife made from a cultivated source of root materials. The cultivation program was the result of more than a decade of effort focused on achieving a physical and phytochemical profile identical to previously supplied wildcrafted material. Today's Rhodiolife has been called by industry observers "the most sustainable Rhodiola rosea on the market today."
Headquartered in Morristown, NJ, USA, PLT Health Solutions is a trusted discoverer, developer, and marketer of high-quality, scientifically supported ingredients that enhance health and functionality. As a leading ingredients innovator, PLT's global network of strategic partnerships provides unique access to impactful solutions. By delivering an unsurpassed mix of expertise, resources, and service, PLT is committed to helping both its strategic partners and valued customers grow.
Media Contact: Mark Falconer
Sciencewerks, LLC
Voice: 407-412-9702
E-mail: 349480@email4pr.com
Company Contact: Steve Fink, Vice President, Marketing
PLT Health Solutions, Inc
Voice: 973-984-0900 x214
E-mail: 349480@email4pr.com
Trends, opportunities and forecast in Middle Eastern and North African active pharmaceutical ingredient (API) market to 2027 by synthesis type (synthetic chemical, biotech and biologics, plant extracts, fermentation, and others), manufacturer type (captive API and merchant API), therapeutic area (cardiology, oncology, neurology, ophthalmology, orthopedics, pulmonology, aliment, anti-inflammatory, and others ), product form (liquid API and powder API), molecule type (large molecule and small molecule), and drug type (branded, generic, and over-the-counter).
New York, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Middle Eastern and North African Active Pharmaceutical Ingredient (API) Market" - https://www.reportlinker.com/p06362778/?utm_source=GNW
Middle Eastern and North African Active Pharmaceutical Ingredient Market Trends and Forecast
The future of the Middle Eastern and North African active pharmaceutical ingredient market looks promising with opportunities in cardiology, oncology, neurology, ophthalmology, orthopedics, pulmonology, aliment, anti-inflammatory therapeutic areas. The Middle Eastern and North African active pharmaceutical ingredient market is expected to reach $5.4 billion in 2027 and grow with a CAGR of 7.7% from 2022 to 2027. The major drivers for this market are rise in growth of pharmaceutical production and research and development of new drugs.
Emerging Trends in Middle Eastern and North African Active Pharmaceutical Ingredient Market
Emerging trends, which have direct impact on the dynamics of the industry, include an increase in the adoption of advanced technologies in API manufacturing, increasing demand for high potency APIs, and increasing adoption of binder for development of peroxide sensitive APIs.
MENA Active Pharmaceutical Ingredient Market by Segment
In this market, synthetic chemical is the largest synthesis type market, whereas cardiology is larger in therapeutic area. Growth in various segment of the MENA API market are given below:
The study includes trends and forecast for the Middle Eastern and North African active pharmaceutical ingredient market by synthesis type, manufacturer type, therapeutic area, product form, molecule type, and drug type as follows:
Middle Eastern and North African Active Pharmaceutical Ingredient Market by Synthesis Type [Value ($ Million) for 2016 – 2027]:
• Synthetic Chemical
• Biotech and Biologics
• Plant Extracts
• Fermentation
• Others
Middle Eastern and North African Active Pharmaceutical Ingredient Market by Manufacturer Type [Value ($ Million) for 2016 – 2027]:
• Captive APIs
• Merchant APIs
Middle Eastern and North African Active Pharmaceutical Ingredient Market by Therapeutic Area [Value ($ Million) for 2016 – 2027]:
• Cardiology
• Oncology
• Neurology
• Ophthalmology
• Orthopedics
• Pulmonology
• Aliment
• Anti-Inflammatory
• Others
Middle Eastern and North African Active Pharmaceutical Ingredient Market by Product Form [Value ($ Million) for 2016 – 2027]:
• Liquid API
• Powder API
Middle Eastern and North African Active Pharmaceutical Ingredient Market by Molecule Type [Value ($ Million) for 2016 – 2027]:
• Large Molecule
• Small Molecule
Middle Eastern and North African Active Pharmaceutical Ingredient Market by Drug Type [Value ($ Million) for 2016 – 2027]:
• Branded
• Generic
• Over-the-Counter
List of Middle Eastern and North African Active Pharmaceutical Ingredient Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies, active pharmaceutical ingredient companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the active pharmaceutical ingredient companies profiled in this report include-
• Pfizer
• Teva Pharmaceutical
• GSK
• Sun Pharmaceutical
• Novartis
• Aurobindo
• Merck& Co.
• BASF
• Julphar
• AbbVie
Middle Eastern and North African Active Pharmaceutical Ingredient Market Insights
• The analyst forecasts that synthetic chemical will remain the largest segment over the forecast period due to continuous research and development activities and growing demand of synthetic chemical APIs in therapeutic areas.
• Within this market, cardiology will remain the largest therapeutic area segment over the forecast period due to increasing cardiovascular diseases and increase in geriatric population.
Features of the Middle Eastern and North African Active Pharmaceutical Ingredient Market
• Market Size Estimates: Middle Eastern and North African active pharmaceutical ingredient market size estimation in terms of value ($M) shipment.
• Trend and Forecast Analysis: Market trends (2016-2021) and forecast (2022-2027) by various segments.
• Segmentation Analysis: Middle Eastern and North African active pharmaceutical ingredient market size by various segments, such as synthesis type, manufacturer type, therapeutic area, product form, molecular type, and drug type in terms of value.
• Country Analysis: Middle Eastern and North African active pharmaceutical ingredient market breakdown by the Saudi Arabia.
• Growth Opportunities: Analysis of growth opportunities in different synthesis types, manufacturer types, therapeutic areas, product forms, molecular types, and drug types for the Middle Eastern and North African active pharmaceutical ingredient market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the Middle Eastern and North African active pharmaceutical ingredient market.
• Analysis of competitive intensity of the industry based on Porter’s Five Forces model
FAQ
Q1. What is the Middle Eastern and North African active pharmaceutical ingredient market size?
Answer: The global Middle Eastern and North African active pharmaceutical ingredient market is expected to reach an estimated $5.4 billion by 2027.
Q2. What is the growth forecast for Middle Eastern and North African active pharmaceutical ingredient market?
Answer: The Middle Eastern and North African active pharmaceutical ingredient market is expected to grow at a CAGR of ~7.7% from 2022 to 2027.
Q3. What are the major drivers influencing the growth of the Middle Eastern and North African active pharmaceutical ingredient market?
Answer: The major drivers for this market are rise in growth of pharmaceutical production and research and development of new drugs.
Q4. What are the major therapeutic areas for the Middle Eastern and North African active pharmaceutical ingredient market?
Answer: Cardiology, oncology, neurology, ophthalmology, orthopedics, pulmonology, aliment, and anti-Inflammatory are the major therapeutic areas of the Middle Eastern and North African active pharmaceutical ingredient market.
Q5. What are the emerging trends in Middle Eastern and North African active pharmaceutical ingredient market?
Answer: Emerging trends, which have a direct impact on the dynamics of the industry, include increasing adoption of advanced technologies in API manufacturing, increasing demand for high potency APIs, and increasing adoption of binder for development of peroxide sensitive APIs.
Q6. Who are the key Middle Eastern and North African active pharmaceutical ingredient companies?
Answer: Some of the key Middle Eastern and North African active pharmaceutical ingredient companies are as follows:
• Pfizer
• Teva Pharmaceutical
• GSK
• Sun Pharmaceutical
• Novartis
• Aurobindo
• Merck& Co.
• BASF
• Julphar
• AbbVie
Q7. Which will be the largest synthesis type segment in the Middle Eastern and North African active pharmaceutical ingredient market in the future?
Answer: The analyst forecasts that synthetic chemical will remain the largest synthesis segment over the forecast period due to continuous research and development activities and growing demand for synthetic chemical APIs in therapeutic areas.
Q8. In Middle Eastern and North African active pharmaceutical ingredient market, which region is expected to be the largest in the next five years?
Answer: Asia Pacific is expected to be the largest region over the next five years.
Q9. Do we receive customization in this report?
Answer: Yes, The analyst provides 10% customization without any additional cost.
This report answers following 11 key questions
Q.1 What are some of the most promising potential, high-growth opportunities for the Middle Eastern and North African active pharmaceutical ingredient market by synthesis type (synthetic chemical, biotech and biologics, plant extracts, fermentation, and others), manufacturer type (captive apis and merchant apis), therapeutic area (cardiology, oncology, neurology, ophthalmology, orthopedics, pulmonology, aliment, anti-inflammatory, and others ), product form (liquid api and powder api), molecule type (large molecule and small molecule), and drug type (branded, generic, and over-the-counter)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which country will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the Middle Eastern and North African active pharmaceutical ingredient market?
Q.5 What are the business risks and threats to the Middle Eastern and North African active pharmaceutical ingredient market?
Q.6 What are the emerging trends in the active pharmaceutical ingredient market and the reasons behind them?
Q.7 What are some changing demands of customers in this active pharmaceutical ingredient market?
Q.8 What are the new developments in this active pharmaceutical ingredient market? Which companies are leading these developments?
Q.9 Who are the major players in this active pharmaceutical ingredient market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this active pharmaceutical ingredient market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the Middle Eastern and North African active pharmaceutical ingredient market?
Read the full report: https://www.reportlinker.com/p06362778/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
If you love cooking with lentils, you already know that the protein-, fiber-, and mineral-rich legumes (via Healthline) tend to have an earthy flavor that can sometimes taste a bit one-note. For that reason, it's often recommended to add an acidic ingredient such as lemon juice or vinegar to them once they're cooked, whose brightness can help lift the legumes' flavor (via Lentils.org).
That's a strategy employed by Food Network cooking show host Ina Garten, who adds a slip of red wine vinegar to her hearty lentil soup featuring green lentils, leeks, and tomato paste. When testing recipes, Garten told Delish, she's "not just looking for the flavor and the texture. I'm looking for some edge that kind of wakes everything up." In the case of this lentil soup, she explained to the outlet, she felt the soup was nearly there, but was "kind of missing something. I just wandered to the refrigerator and pulled out some red wine vinegar and added just a splash to the huge pot. And that was it."
So the next time lentil soup graces your stove, do as Garten does and hit it with some red wine vinegar (In a lentil soup of her own, Martha Stewart advices adding just a spoonful).
The Jets tried. Wilson failed. And now, White has instantly proven he is the missing ingredient for the team’s playoff push. The Jets beat the Bears31-10 in Week 12. White put up a sensational stat line: 22-of-28, 315 yards, three touchdowns and quarterback rating of 149.3.
"Mike was efficient with the football," coach Robert Saleh said postgame. "He did a great job. He didn’t need to be anybody but Mike White. He didn’t need to be the Greatest Show on Turf. He just needed to play within himself and I think he did that. … He made the easy look easy."
Now that we’ve seen how well White fits with the other pieces on this Jets team, it’s hard to imagine the Jets turning back to Wilson this year, even if that’s what Saleh promised.
And the win wasn’t even really about White. It was about all the other guys. That was the point. Over the next few weeks, White won’t be the story. And that’ll be exactly what the Jets need. They don’t need their quarterback to be brilliant or bold or brazen. They don’t need him to make headlines. They just need him to be quiet and competent.
Now, there’s a caveat. (There’s always a caveat.) The Bears are among the league’s worst defenses. So that certainly helped the Jets come away from this game looking brilliant for making the switch at quarterback. Chicago was allowing the sixth-most points per game heading into this week. The Bears’ successes have mostly come as a product of quarterback Justin Fields, who did not play in this game due to a shoulder injury.
There wasn’t much in the way of pressure on White. He didn’t need to lead a game-winning drive. He didn’t have to duel another good offense. He never had to press — he didn’t have to push himself. Everything just clicked. And in defense of Wilson, he did actually lead a few fourth-quarter comebacks and game-winning drives.
So White will face pressure. And at some point, he will regress. There will be a week — or multiple weeks — when White looks bad. But White proved he could run the Jets system. As harsh as it sounds, that’s more than Wilson did in his weeks as a starter. The New York Jets had been actively avoiding their passing offense for weeks. They had to carry Wilson in the offense. They had to prevent him from losing the game. They won’t have to worry about that as much with White.
This week, White looked like the mechanic that the Jets’ machine needed. He oiled a squeaky wheel in Elijah Moore, who enjoyed his best game of the year with two catches, 64 yards and a touchdown. (Moore demanded a trade earlier this season after not getting enough targets.) Garrett Wilson — the man who called the Jets offense "sorry" last week — also put up an impressive game, with five catches for 94 yards and two touchdowns.
The Jets passing offense isn’t going to do this every week. They’re going to keep leaning on their ground game. They’re going to keep leaning on their defense. White, after all, struggled in a prolonged body of work in 2021, when he served in relief of Wilson last year. The difference is that Garrett Wilson has instantly looked like a competent WR1, the offensive line has proven powerful, and the running backs are gashing teams at a much higher clip. With White operating as a game-manager at quarterback, they don’t have to lean as hard on those strengths. Their passing offense might not be as much of a glaring weakness.
In short time, the Jets could look like one of the more dangerous teams in the NFL. Because for weeks, it was easy to doubt New York.
Why? Zach Wilson.
It was that simple.
New York simply couldn’t make the playoffs — let alone win a playoff game — with a quarterback who was struggling so abundantly.
If White can play half as well as he did in Week 12, New York should be able to compete against the Minnesota Vikings next week and the Buffalo Bills the week after. The Jets clearly had one missing ingredient: a competent quarterback. That’s what White showed he is, at least for a game. And that’s why the Jets should have more hope than ever that they can compete for a playoff spot.
Prior to joining FOX Sports as the AFC East reporter, Henry McKenna spent seven years covering the Patriots for USA TODAY Sports Media Group and Boston Globe Media. Follow him on Twitter at@McKennAnalysis.
Get more from National Football LeagueFollow your favorites to get information about games, news and more
There are very few things on earth as sacred and as beautiful as butter. Spread the heavenly miracle on just about anything at all and it’s instantly improved. Give me your whipped, your balled, your boarded. There isn’t a form butter can take on that I will not devour with adoration. If they made butter popsicles, I’d be the first in line at the ice cream truck. So it goes without saying, I love a well-made, velvety butter sauce. Of these, there are many, each unique and as pleasant as they come. They can be flavored with just about anything fromvinegar to wine to herbs to egg yolks. But did you know that you can make a delightfully French, beautifully savory sauce just by combining butter and water in exactly the right way?
Beurre Monté, directly translated from French, means to “mount with butter”, meaning to top, or finish a dish with the sacred ingredient. Often chefs will “mount” a sauce or a soup with butter as a final touch, adding texture and richness to their dish. This sauce is a play on that, in a sense. Beurre Monté’s uses are plenty, and its flavor extraordinary. And if you know how to make this delicious butter sauce, you will have a very handy, very tasty skill in your culinary tool belt.
Be sure to keep the heat low and steady in order to maintain emulsification. If your sauce gets too hot or too cool, it may break. But…
If it does begin to break, you can whisk in a little cool water re-emulsify the sauce.
Because Beurre Monté can be a bit finicky with consistency, it’s best to make this right before serving. If you do make it ahead of time, be sure to keep your sauce warm before serving.
If you have extra, it can be refrigerated and reheated, but only for use as melted butter. Alternatively, from this stage, the butter could also be clarified.
Beurre Monté recipe
You’ve probably made flavored butter sauces before. As we’ve established, they are truly otherworldly in their deliciousness. But this sauce in particular is especially magical because of its versatility. Use it not only as a sauce for your favorite dishes, but also as a buttery warm holding place for your meats to rest, or a gentle poaching pool for delicate fish. Not only will your dishes be infused with decadent butter flavor, but cooked gently in the most exquisite way possible.
Ingredients:
4 tablespoons – 1 pound of butter, diced into even pieces
Water
Method:
In a saucepan, bring water to a boil.
Reduce the heat to low and begin whisking the butter into the water, one piece at a time to emulsify.
Once the sauce has emulsified, gradually add pieces of butter until you’ve reached the amount of sauce and consistency you desire.
Unlike plain yogurt, Greek yogurt is strained to remove the whey, resulting in a thicker consistency. Greek yogurt can be pretty tart and bitter. However, many brands have picked up on this and decided to add flavors and mix-ins to this popular yogurt to give it a better flavor and appeal to the masses. With that said, this process has taken a product that naturally contains high-quality ingredients and diminished the quality for the sake of taste and flavor.
All dairy-based yogurts are going to contain some naturally-occurring sugar, however, you'll want to keep an eye out for excess added sugar.
"When you look at the label, you might want to avoid Greek yogurts that contain a ton of added sugar," says registered dietitian Breanna Woods. "I usually look for something with 10 grams or less per serving if I'm shopping for individual cups."
According to the American Heart Association, most women should consume no more than 24 grams of added sugar per day, while men should consumer no more than 36 grams.
Additionally, Woods advises to look out for artificial sweeteners, which have a tendency to trigger headaches or bloating.
One last ingredient Woods says to be aware of is chicory root. "This is a prebiotic fiber so it's mostly beneficial, as it feeds good bacteria in the gut. However, it could cause gas, bloating, and even diarrhea for some people, especially anyone intolerant to FODMAPs or anyone not used to taking in a lot of fiber."
With that information in mind, here are eight greek yogurts with the lowest quality ingredients that you can buy right now.
PER 3/4 CUP: 180 calories, 2.5 g fat (1.5 g saturated fat), 20 mg cholesterol, 75 mg sodium, 36 g carbs (0 g fiber, 21 g sugar, 18 g added sugar), 13 g protein
Out of all of the Greek yogurts on this list, this vanilla bean one has the highest amount of added sugar at a whopping 18 grams per serving. However, you'll find a significant amount of vitamin D and vitamin A, which is an added benefit to this brand.
PER 1 CUP: 90 calories, 0 g fat, 10 mg cholesterol, 55 mg sodium, 7 g carbs (0 g fiber, 5 g sugar, 0 g added sugar), 15 g protein
While this Greek yogurt has a significant amount of protein, don't let that fool you into thinking that it's one of the better options. Like Woods mentioned above, this Greek yogurt contains chicory root fiber, which has been shown to cause gas, bloating, and diarrhea in some people, so you'll want to proceed with caution.
PER 2/3 CUP: 200 calories, 8 g fat (5 g saturated fat), 30 mg cholesterol, 105 mg sodium, 25 g carbs (0 g fiber, 23 g sugar, 15 g added sugar), 7 g protein
Although this Greek yogurt contains no natural flavors, it is loaded with added sugars which Woods advises to keep a watchful eye on. With that said, there's only seven grams of protein per serving, which is a lot less than other brands, so you may not feel as satisfied after eating a cup of this.
PER 1 CONTAINER: 160 calories, 4 g fat (2.5 g saturated fat), 10 mg cholesterol, 65 mg sodium, 22 g carbs (<1 g fiber, 18 g sugar, 14 g added sugar), 8 g protein
After taking a glance at the nutrition label, you'll see ingredients like caramel color, guar gum, cocoa butter, etc. These aren't ingredients you'd find in your typical container of Greek yogurt and they certainly aren't the highest quality.6254a4d1642c605c54bf1cab17d50f1e
"Yogurts with fun mix-ins like Cookies & Cream Chobani Flip are usually much higher in added sugar," says Woods. "They're delicious as a snack every now and then, but not something I would eat daily."
PER 1 CUP: 160 calories, 4 g fat (2.5 g saturated fat), 15 mg cholesterol, 45 mg sodium,19 g carbs (0 g fiber, 19 g sugar, 14 g added sugar), 11 g protein
This orange cream Greek yogurt contains nearly a third of the recommended daily value of added sugar per serving which to mention is a single cup. Additionally, you'll see different gums on the ingredients list like xanthan gum and locust bean gum which you'll want to try to avoid to prevent unwanted digestive issues.
PER 2/3 CUP: 140 calories, 0 g fat (0 g saturated fat), 5 mg cholesterol, 50 mg sodium, 21 g carbs (0 g fiber, 19 g sugar, 19 g added sugar), 14 g protein
Vanilla Greek yogurt is a solid choice when looking for a flavored version that goes down easier than the traditional tarte flavor. With that said, this nonfat yogurt has 13 grams of added sugar per serving which is nearly double the amount of natural sugar present.
It also contains a bioengineered food ingredient according to the label so when talking about high quality ingredients this lands at the bottom of the list.
PER 1 CONTAINER: 120 calories, 2.5 g fat ( 1.5 g saturated fat), 15 mg cholesterol, 45 mg sodium, 13 g carbs ( 0 g fiber, 11 g sugar, 7 g added sugar), 12 g protein
If you're looking for flavorful Greek yogurt, then this strawberry one might pique your interest. With that in mind, it does contain 15% of the daily recommended value of added sugar which can be detrimental to health over time.
PER 1 CONTAINER: 170 calories, 4 g fat ( 2 g saturated fat), 15 mg cholesterol, 150 mg sodium, 8 g carbs (0 g fiber, 3 g sugar, 0 g added sugar, <1g sugar alcohol), 25 g protein
On the ingredients list, you'll notice that this Greek yogurt contains erythritol and sunflower oil. Erythritol is a sugar substitute that can cause bloating, gas, nausea, and headaches as Woods mentioned above. Additionally, sunflower oil has been shown to lead to weight gain and increased inflammation in the body.
